Navigation Links
New test takes guesswork out of diagnosing early stage Alzheimer's disease
Date:3/26/2010

A new test developed by Japanese scientists may revolutionize how and when physicians diagnose Alzheimer's disease. According to a research report published online in The FASEB Journal (http://www.fasebj.org), the new test measures proteins in the spinal fluid known to be one of the main causes of brain degeneration and memory impairment in Alzheimer's patients: high molecular weight A-Beta oligomers. This tool, once fully implemented, would allow physicians to diagnose and treat Alzheimer's disease in its early stages, a time when diagnosing the disease is very difficult.

"Alzheimer's disease is a growing problem, due to aging of the population in all developed countries," said Takahiko Tokuda, M.D., Ph.D., a researcher from the Department of Neurology at the Kyoto Prefectural University of Medicine Graduate School of Medical Science in Japan who was involved in the work. "We hope that our new diagnostic test will, in the future, significantly improve the lives of people with Alzheimer's disease, and lead to much better ways of treating this devastating disorder."

Scientists developed a tool (enzyme-linked immunosorbent assay) that specifically measures A-Beta oligomers. They then compared the levels of these protein aggregates in human cerebrospinal fluid samples among three groups of people: 1) patients with diagnosed Alzheimer's disease; 2) patients with mild cognitive impairment who went on to develop Alzheimer's disease; and 3) a control group with no symptoms of Alzheimer's disease. Results showed that the levels of the a fragments being measured directly correlated to the extent of memory impairment, with the highest levels found in those with confirmed Alzheimer's and intermediate levels in those with mild cognitive impairment. This shows that by measuring the levels of A-Beta oligomers in cerebrospinal fluid, physicians may be able to identify Alzheimer's disease before it can be clinically diagnosed using current methods.

"Baby boomers are getting older and Alzheimer's disease will have a tremendous impact on the memory of a generation and the lives of its children," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This test is not only useful for the early detection of Alzheimer's disease, but promises to be a marker for the efficacy of newer treatments that are already on the drawing board."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology technology :

1. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
2. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
3. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
4. Ground-Breaking Conference Takes on Abortion
5. White Paper Advises Pharma Manufacturers on How to Select an Aseptic Fill/Finish Contractor, Avoid the Most Common Mistakes
6. Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
7. Tepper School Team Takes Top Honors at Global Moot Corp(R) Competition
8. Board Certified Dermatologist and President-Elect of the Dermatologic Society of Greater New York, Dr. Lance H. Brown Takes His Comprehensive Practice to East Hampton, NY
9. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
10. Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level
11. Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in a published evaluation of multiple immunoassay-based threat detection technologies by researchers ... Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have the ...
(Date:2/23/2017)... 23, 2017 Aviva Systems Biology Corporation ... acquisition of GenWay Biotech Incorporated, a protein solutions ... product offering for both the research and diagnostic ... and enhance capabilities for both entities. GenWay,s 18 years ... will nicely complement ASB,s objective to become a ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):